Journal ArticleDOI
Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
Hugh A. Sampson,Anne Muñoz-Furlong,Ronna L. Campbell,N. Franklin Adkinson,S. Allan Bock,Amy M. Branum,Simon G A Brown,Carlos A. Camargo,Rita K. Cydulka,Stephen J. Galli,Jane Gidudu,Rebecca S. Gruchalla,Allen D. Harlor,David L. Hepner,Lawrence M. Lewis,Phillip Lieberman,Dean D. Metcalfe,Robert E. O'Connor,Antonella Muraro,Amanda Rudman,Cara Schmitt,Debra Scherrer,F. Estelle R. Simons,Stephen Thomas,Joseph P. Wood,Wyatt W. Decker +25 more
Reads0
Chats0
TLDR
There is no universal agreement on the definition of anaphylaxis or the criteria for diagnosis, so representatives from 16 different organizations or government bodies, including representatives from North America, Europe, and Australia, to continue working toward a universally accepted definition.Abstract:
There is no universal agreement on the definition of anaphylaxis or the criteria for diagnosis. In July 2005, the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network convened a second meeting on anaphylaxis, which included representatives from 16 different organizations or government bodies, including representatives from North America, Europe, and Australia, to continue working toward a universally accepted definition of anaphylaxis, establish clinical criteria that would accurately identify cases of anaphylaxis with high precision, further review the evidence on the most appropriate management of anaphylaxis, and outline the research needs in this area.read more
Citations
More filters
Journal ArticleDOI
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies
Albert L. Sheffer,Marilyn Campion,Robyn J. Levy,H. Henry Li,Patrick T. Horn,William E. Pullman +5 more
TL;DR: Ecallantide appears to be effective and well tolerated for the treatment of HAE attacks and supports and expands on the results of the phase 3 studies.
Journal ArticleDOI
Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia.
Rafael Otero-Patiño,Álvaro Segura,María Herrera,Yamileth Angulo,Guillermo León,José María Gutiérrez,Jacqueline Barona,Sebastián Estrada,Andres Pereanez,Juan C Quintana,Leidy J. Vargas,Juan Pablo Gómez,A. Díaz,Ana María Suárez,Jorge Fernández,Patricia Ramírez,Patricia E. Fabra,Monica Perea,D. Fernández,Yobana Arroyo,Dalila Betancur,Lady Pupo,Elkin A. Córdoba,C. Eugenio Ramírez,Ana Berta Arrieta,Alcides Rivero,Diana Carolina Mosquera,Nectty Lorena Conrado,Rosina Ortiz +28 more
TL;DR: In conclusion, IgG and F(ab')2 antivenoms, prepared by caprylic acid fractionation, presented similar efficacy and safety profiles for the treatment of B. asper envenomings in Colombia.
Journal ArticleDOI
Kreislaufstillstand in besonderen Situationen
Anatolij Truhlář,Charles D. Deakin,Jasmeet Soar,Gamal Eldin Abbas Khalifa,A. Alfonzo,Joost J.L.M. Bierens,Guttorm Brattebø,Hermann Brugger,Joel Dunning,Silvija Hunyadi-Anticevic,R. W. Koster,David Lockey,Carsten Lott,Peter Paal,Gavin D. Perkins,Gavin D. Perkins,Claudio Sandroni,Karl-Christian Thies,David Zideman,Jerry P. Nolan +19 more
Journal ArticleDOI
Update on rupatadine in the management of allergic disorders.
J Mullol,Jean Bousquet,Claus Bachert,Giorgio Walter Canonica,Ana Giménez-Arnau,Marek L. Kowalski,F. E. R. Simons,Marcus Maurer,Dermot Ryan,Glenis Scadding +9 more
TL;DR: New studies have demonstrated that rupatadine inhibits PAF effects in nasal airways and produces a greater reduction in nasal symptoms than levocetirizine, and a meta‐analysis involving more than 2500 patients has consolidated the clinical evidence for rup atadine in allergic rhinoconjunctivitis in adults and children.
Journal ArticleDOI
Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened?
TL;DR: Why the possibility of conducting randomized placebo-controlled trials with H1-antihistamines, H2-antiharamines, and particularly with glucocorticoids in anaphylaxis should be considered in order to improve the evidence base for treatment and guide clinical decision-making is discussed.
References
More filters
Journal ArticleDOI
Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents
TL;DR: Six children and adolescents who died of anaphylactic reactions to foods and seven others who nearly died and required intubation were identified and the failure to recognize the severity of these reactions and to administer epinephrine promptly increases the risk of a fatal outcome.
Journal ArticleDOI
Fatalities due to anaphylactic reactions to foods.
TL;DR: Fatal anaphylactic reactions to foods are continuing to occur, and better characterization might lead to better prevention, and peanuts and tree nuts accounted for more than 90% of the fatalities.
Journal ArticleDOI
Clinical features and severity grading of anaphylaxis
TL;DR: A simple grading system and definition of anaphylaxis has potential value for defining reaction severity in clinical practice and research settings and appears to be the major determinants of reaction severity.
Journal ArticleDOI
Symposium on the Definition and Management of Anaphylaxis: Summary report
Hugh A. Sampson,Anne Muñoz-Furlong,S. Allan Bock,Cara Schmitt,Robert Bass,Badrul A. Chowdhury,Wyatt W. Decker,Terence J. Furlong,Stephen J. Galli,David B.K. Golden,Rebecca S. Gruchalla,Allen D. Harlor,David L. Hepner,Marilyn Howarth,Allen P. Kaplan,Jerrold H. Levy,Lawrence M. Lewis,Phillip Lieberman,Dean D. Metcalfe,Ramon Murphy,Susan M. Pollart,Richard S. Pumphrey,Lanny J. Rosenwasser,F. Estelle R. Simons,Joseph P. Wood,Carlos A. Camargo +25 more
TL;DR: This dissertation aims to provide a history of medical marijuana use in the United States and Canada over a 40-year period from 1989 to 2002, with a focus on the period up to and including the year ending in 2002.
Journal ArticleDOI
Advances in H1-Antihistamines
TL;DR: There are clinically relevant differences among H1-antihistamines in their pharmacology and safety profiles in allergic rhinoconjunctivitis and chronic urticaria.